ArticleNPJ Parkinson's disease2025
Triglyceride-glucose index predicts cognitive decline and striatal dopamine deficiency in Parkinson disease in two cohorts.
Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- CSF proteomic pathway alterations and caudate dopamine transporter deficits predict cognitive vulnerability in early Parkinson's disease.European journal of nuclear medicine and molecular imaging · 2026Article
- Triglyceride-Glucose-Related Indexes as Risk Factors for Vision-Threatening Ocular Diseases: A Prospective UK Biobank Study.Investigative ophthalmology & visual science · 2026Article
- GLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach.Trends in molecular medicine · 2026Review
- Metabolic dysfunction and insulin resistance across major dementias: A comprehensive narrative review of the TyG index as a predictive marker.Metabolism open · 2026Review
- Association of Triglyceride-Glucose Index With In-Hospital Malignant Arrhythmias in Older Patients With Diabetes Mellitus and Left Ventricular Aneurysm: A Retrospective Study.Reviews in cardiovascular medicine · 2026Article
- Association between triglyceride-glucose index and vascular dementia in ICU patients with cerebrovascular disease: a retrospective study based on the MIMIC-IV database.BMC neurology · 2026Article
- Preventing Parkinson's disease in the context of movement disorders: a narrative review of current evidence and future directions.Neurological research and practice · 2026Review
- Insulin Resistance Surrogates and Cognitive Impairment in Parkinson's Disease: A Cross-Sectional Study with Interpretable Machine Learning.Biomedicines · 2026Article
- Association between the triglyceride-glucose index and disease severity in non-diabetic Parkinson's disease patients.Frontiers in aging neuroscience · 2026Article
- Triglyceride-glucose index is associated with cerebral small vessel disease-related motor impairment in Parkinson's disease: a mediation analysis.Frontiers in aging neuroscience · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Heterogeneity is an important feature of cognitive impairment in patients with Parkinson's disease (PD), with emerging evidence linking insulin resistance to accelerated cognitive decline. Our investigation examined the relationship between the triglyceride-glucose (TyG) index-a marker of insulin resistance-and cognition and striatal dopamine transporter (DAT) alterations in PD through cross-sectional and longitudinal analyses. In the primary cohort, higher TyG correlated with lower Mini-Mental State Examination (MMSE) scores (p < 0.001) and increased dementia risk (p = 0.014). Longitudinal analysis in the PPMI cohort showed higher baseline TyG predicted greater Montreal Cognitive Assessment (MoCA) decline (p = 0.019) and reduced DAT activity in caudate (p = 0.033) and putamen (p = 0.019) over 4 years.DAT activity in the caudate mediated 24.1% of the TyG index's longitudinal effect on MoCA scores, while the TyG index mediated 16.9% of CSF GLP-1R's effect. These results highlight the TyG index as a potential biomarker for identifying PD patients at higher risk of cognitive impairment.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.